AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15730685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal template overlain with thin split‐thickness autograft
Number of subjects: 20
Study 15730685 — intervention group
Group type: COMPARATOR
Intervention: Thin split‐thickness autograft only (Control)
Number of subjects: 20
Study 11518688 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 0
Study 11518688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal + acarbose
Number of subjects: 0
Study 11518688 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-free meal after sucrose and acarbose ingestion
Number of subjects: 0
Study 11518688 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 9017481 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 46
Study 9017481 — intervention group
Group type: COMPARATOR
Intervention: Saline (2-cc vials)
Number of subjects: 46
Study 8357508 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Design Reach toothbrush
Number of subjects: 90
Study 8357508 — intervention group
Group type: COMPARATOR
Intervention: Crest Complete toothbrush
Number of subjects: 90
Study 8357508 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B 40 toothbrush
Number of subjects: 90
Study 3531313 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 105
Study 3531313 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 105
Study 3531313 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 105
Study 3531313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined omeprazole groups
Number of subjects: 105
Study 3531313 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg vs Ranitidine
Number of subjects: 105
Study 3531313 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 6 months
Number of subjects: 105
Study 29235360 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20 with gemcitabine and nab-paclitaxel
Number of subjects: 0
Study 29235360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional parenting intervention (4-6 home visits between 18 and 22 months CA)
Number of subjects: 60
Study 27402332 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional parenting intervention
Number of subjects: 60
Study 27402332 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 24107382 — intervention group
Group type: EXPERIMENTAL
Intervention: High concern about falling (FES-I ≥ 20)
Number of subjects: 409
Study 24107382 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related variables, functional performance tests, physical activity, quality of life
Number of subjects: 409
Study 24107382 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulties in instrumental activities of daily living, balance, outdoor mobility
Number of subjects: 409
Study 22622345 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 0
Study 22622345 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study 22622345 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 0
Study 20864600 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRB+PT (Selective Nerve Root Block + Physical Therapy)
Number of subjects: 44
Study 20864600 — intervention group
Group type: COMPARATOR
Intervention: SNRB (Selective Nerve Root Block alone)
Number of subjects: 44
Study 18343300 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions (specifics not available)
Number of subjects: 0
Study 18343300 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical treatments (specifics not available)
Number of subjects: 0
Study 15259396 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI during incidental encoding and recognition tasks for colored and black and white photographs
Number of subjects: 10
Study 15259396 — intervention group
Group type: COMPARATOR
Intervention: fMRI during incidental encoding and recognition tasks
Number of subjects: 10
Study 9688386 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 75 IU FSH per ampoule, two ampoules on cycle day 4, one ampoule on days 6 and 8 (total four ampoules)
Number of subjects: 63
Study 9688386 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: two ampoules on days 4, 6 and 8 (total six ampoules)
Number of subjects: 63
Study 9688386 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: two ampoules on days 4, 6, 8 and 10 (total eight ampoules)
Number of subjects: 63
Study 7865199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-age classes
Number of subjects: 48
Study 7865199 — intervention group
Group type: COMPARATOR
Intervention: Same-age classes
Number of subjects: 48
Study 2599125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hickman‐Broviac (HB) catheter
Number of subjects: 447
Study 2599125 — intervention group
Group type: EXPERIMENTAL
Intervention: Port‐a‐Cath (PAC)
Number of subjects: 447
Study 1205398 — intervention group
Group type: EXPERIMENTAL
Intervention: Light stimulus provided by a 250 watt bulb lit for 20 minutes
Number of subjects: 143
Study 1205398 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized sequence of light stimulus (on/on/off or off/off/on)
Number of subjects: 143
Study 27629797 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial variables (self-efficacy, treatment expectation, social support)
Number of subjects: 200
Study 25261009 — intervention group
Group type: EXPERIMENTAL
Intervention: Handouts with photographs of clinicians
Number of subjects: 186
Study 25261009 — intervention group
Group type: EXPERIMENTAL
Intervention: Handouts with names and roles of clinicians
Number of subjects: 186
Study 25261009 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 186
Study 23341160 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 30 minutes
Number of subjects: 503
Study 23341160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 3 hours
Number of subjects: 503
Study 23341160 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of ß‐lactam antibiotics
Number of subjects: 503
Study 23341160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of ß‐lactam antibiotics
Number of subjects: 503
Study 23341160 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion group
Number of subjects: 503
Study 23341160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion group
Number of subjects: 503
Study 22039325 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 85
Study 22039325 — intervention group
Group type: COMPARATOR
Intervention: Heater probe coagulation (HPC)
Number of subjects: 85
Study 19444515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged catheter drainage
Number of subjects: 58
Study 19444515 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 58
Study 17076053 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group intervention targeting improvement of self-concept and overall quality of life
Number of subjects: 52
Study 17076053 — intervention group
Group type: COMPARATOR
Intervention: High quality treatment as usual (control group)
Number of subjects: 52
Study 15017618 — intervention group
Group type: EXPERIMENTAL
Intervention: rifaximin
Number of subjects: 0
Study 11730649 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 426
Study 11730649 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.0015%
Number of subjects: 426
Study 11730649 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 426
Study 9356060 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 0
Study 9356060 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 0
Study 9356060 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral legs)
Number of subjects: 0
Study 9114913 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily dosing (o.d.) of modified-release carbamazepine (CBZ-MR)
Number of subjects: 14
Study 9114913 — intervention group
Group type: COMPARATOR
Intervention: Twice daily dosing (b.d.) of modified-release carbamazepine (CBZ-MR)
Number of subjects: 14
Study 3303997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladosporium allergen preparation
Number of subjects: 11
Study 3303997 — intervention group
Group type: COMPARATOR
Intervention: Histamine placebo
Number of subjects: 11
Study 31838029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metolazone
Number of subjects: 60
Study 31838029 — intervention group
Group type: EXPERIMENTAL
Intervention: IV chlorothiazide
Number of subjects: 60
Study 31838029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 60
Study 31838029 — intervention group
Group type: COMPARATOR
Intervention: Metolazone
Number of subjects: 60
Study 31347763 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing alone
Number of subjects: 0
Study 31347763 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating upper extremity muscle contractions
Number of subjects: 0
Study 31347763 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing synchronized with alternating contractions
Number of subjects: 0
Study 31347763 — intervention group
Group type: COMPARATOR
Intervention: Neutral control task
Number of subjects: 0
Study 28207912 — intervention group
Group type: COMPARATOR
Intervention: OCD participants during habituation
Number of subjects: 80
Study 28207912 — intervention group
Group type: COMPARATOR
Intervention: OCD participants during acquisition
Number of subjects: 80
Study 28207912 — intervention group
Group type: COMPARATOR
Intervention: OCD participants during extinction
Number of subjects: 80
Study 28207912 — intervention group
Group type: COMPARATOR
Intervention: HC participants during acquisition
Number of subjects: 80
Study 28207912 — intervention group
Group type: COMPARATOR
Intervention: HC participants during extinction
Number of subjects: 80
Study 28207912 — intervention group
Group type: COMPARATOR
Intervention: OCD participants overall
Number of subjects: 80
Study 26177035 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT scan of the lumbar spine prior to diagnostic infiltration of the medial branches
Number of subjects: 29
Study 26177035 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic infiltrations with local anesthetics
Number of subjects: 29
Study 23382120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid problem-based learning (hybrid-PBL)
Number of subjects: 205
Study 23382120 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 205
Study 21435540 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-anchored treatment (IA group)
Number of subjects: 30
Study 21435540 — intervention group
Group type: COMPARATOR
Intervention: Conventional edgewise treatment (non-IA group)
Number of subjects: 30
Study 21435540 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 19308298 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based stress management intervention (3 months)
Number of subjects: 102
Study 19308298 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 102
Study 17112361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (PCA)
Number of subjects: 60
Study 17112361 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA plus continuous femoral nerve block
Number of subjects: 60
Study 17112361 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA plus continuous posterior lumbar plexus block
Number of subjects: 60
Study 17112361 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 14586494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 8
Study 14586494 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 8
Study 11924697 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-patients seeking help from any consultant
Number of subjects: 153
Study 11924697 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-patients seeking help from a professional consultant
Number of subjects: 153
Study 11924697 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-patients discussing suicide with any consultant
Number of subjects: 153
Study 11924697 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-patients discussing suicide with professionals
Number of subjects: 153
Study 9135487 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the breast
Number of subjects: 381
Study 9135487 — intervention group
Group type: EXPERIMENTAL
Intervention: > or = 10 lymph nodes found in the axillary specimen
Number of subjects: 381
Study 9135487 — intervention group
Group type: COMPARATOR
Intervention: < 10 lymph nodes found in the axillary specimen
Number of subjects: 381
Study 9135487 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative wound complications
Number of subjects: 381
Study 9135487 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed patients
Number of subjects: 381
Study 9135487 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients < 65 years of age
Number of subjects: 381
Study 9135487 — intervention group
Group type: COMPARATOR
Intervention: Retired patients
Number of subjects: 381
Study 9135487 — intervention group
Group type: COMPARATOR
Intervention: Patients > = 65 years of age
Number of subjects: 381
Study 8093742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 3522
Study 8093742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3522
Study 3039431 — intervention group
Group type: EXPERIMENTAL
Intervention: adriamycin + VM 26 + 5-Fluorouracil (5-FU)
Number of subjects: 47
Study 3039431 — intervention group
Group type: COMPARATOR
Intervention: mAMSA + VM 26 + 5-Fluorouracil (5-FU)
Number of subjects: 47
Study 3039431 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 47
Study 29672097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 163
Study 29672097 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 163
Study 29672097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue catastrophizing
Number of subjects: 163
Study 29672097 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 163
Study 26754181 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + DL
Number of subjects: 60
Study 26754181 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 24163282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 178
Study 24163282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 178
Study 24163282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Sumatriptan (25 mg and 50 mg)
Number of subjects: 178
Study 24163282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 22190398 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA vaccine (formalin treated, alum adsorbed, or both)
Number of subjects: 186
Study 22190398 — intervention group
Group type: EXPERIMENTAL
Intervention: formalin‐only‐treated rPA
Number of subjects: 186
Study 22190398 — intervention group
Group type: EXPERIMENTAL
Intervention: alum‐adsorbed rPA
Number of subjects: 186
Study 22190398 — intervention group
Group type: EXPERIMENTAL
Intervention: two dosages of rPA
Number of subjects: 186
Study 22190398 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA vaccine
Number of subjects: 186
Study 22190398 — intervention group
Group type: COMPARATOR
Intervention: AVA (licensed vaccine)
Number of subjects: 186
Study 22190398 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐rPA measured by ELISA
Number of subjects: 186
Study 21090159 — intervention group
Group type: EXPERIMENTAL
Intervention: A-mode ultrasound
Number of subjects: 140
Study 21090159 — intervention group
Group type: COMPARATOR
Intervention: Sinus computed tomography (CT)
Number of subjects: 140
Study 18534975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.7 mg/kg body weight, single oral dose)
Number of subjects: 27
Study 18534975 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27
Study 17135987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and cognitive-behavioral therapy (COMB)
Number of subjects: 439
Study 17135987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 17135987 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439
Study 17135987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 12761722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 12761722 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 12761722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch surveillance guidelines
Number of subjects: 0
Study 11011281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% estradiol gel (Gel A)
Number of subjects: 48
Study 8627394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced professional practice model
Number of subjects: 5
Study 8627394 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5
Study 1597214 — intervention group
Group type: EXPERIMENTAL
Intervention: Diving (D, 45 s)
Number of subjects: 22
Study 1597214 — intervention group
Group type: COMPARATOR
Intervention: Cold Pressor Test (CPT, 2 min)
Number of subjects: 22
Study 6374193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) administered 3 times a day at a daily dosage of 750 mg for 3 to 5 days.
Number of subjects: 243
Study 6374193 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (CEX) administered 4 times a day at a daily dosage of 1,000 mg for 3 to 5 days.
Number of subjects: 243
Study 6374193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL)
Number of subjects: 243
Study 6374193 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (CEX)
Number of subjects: 243
Study 31521136 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention to support home exercise adherence
Number of subjects: 0
Study 31521136 — intervention group
Group type: COMPARATOR
Intervention: No SMS intervention
Number of subjects: 0
Study 29335742 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-in-oil emollient containing licochalcone A, omega-6-fatty acids, ceramide 3, and glycerol
Number of subjects: 0
Study 29335742 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 26301519 — intervention group
Group type: EXPERIMENTAL
Intervention: AOT plus BCI-FES
Number of subjects: 30
Study 24338076 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based, tailored policy advocacy assistance
Number of subjects: 186
Study 24338076 — intervention group
Group type: COMPARATOR
Intervention: No assistance
Number of subjects: 186
Study 22301087 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy (CBT) for depression and substance use
Number of subjects: 73
Study 22301087 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 73
Study 19852872 — intervention group
Group type: EXPERIMENTAL
Intervention: (6S)-5-methyltetrahydrofolic acid
Number of subjects: 163
Study 19852872 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 163
Study 19852872 — intervention group
Group type: COMPARATOR
Intervention: Folate-rich foods
Number of subjects: 163
Study 18006623 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus spironolactone (group A; n = 25)
Number of subjects: 50
Study 18006623 — intervention group
Group type: COMPARATOR
Intervention: Candesartan alone (group B; n = 25)
Number of subjects: 50
Study 16108771 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of Peginterferon alpha‐2b + ribavirin (Group A)
Number of subjects: 65
Study 16108771 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of Peginterferon alpha‐2b administered twice weekly + ribavirin (Group B)
Number of subjects: 65
Study 12610185 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 1812
Study 12610185 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived high levels of ageism
Number of subjects: 1812
Study 12610185 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived high levels of racism
Number of subjects: 1812
Study 12610185 — intervention group
Group type: EXPERIMENTAL
Intervention: Processes of care
Number of subjects: 1812
Study 10547511 — intervention group
Group type: EXPERIMENTAL
Intervention: Round arch wires
Number of subjects: 28
Study 10547511 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular arch wires
Number of subjects: 28
Study 10547511 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study 9324785 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 205
Study 9324785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 205
Study 9324785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 205
Study 9324785 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 205
Study 1822761 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 2
Study 1822761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6239753 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg meptazinol 4-times daily for up to 3 weeks
Number of subjects: 70
Study 6239753 — intervention group
Group type: COMPARATOR
Intervention: 250 mg diflunisal 4-times daily for up to 3 weeks
Number of subjects: 70